Company Overview

StemBios Technologies, Inc. is an adult stem-cell based biotechnology research company founded in 2010. We are an emerging company focused on the development of novel SB Cells® (StemBios cells) used for therapeutic cell banking, cellular healing and therapeutic approaches to cure common medical conditions and diseases such as neurodegenerative, cardiovascular, metabolic, autoimmune diseases, and cancer.

Within the past two years, we have discovered adult pluripotent stem cells (SB Cells®) from adult blood and bone marrow. By using our purification method, we isolate and collect the SB Cells®, which have a size smaller than 6 µm, from red blood cells and white blood cells. Using flow-cytometry, we distinguish two groups of SB Cells®: SB-1 and SB-2. Since SB-1 and SB-2 cells contain Oct4 and Nanog gene expressions, two markers indicative of embryonic stem cells, we believe that SB Cells® have the potential to act as embryonic stem cells. After purifying SB Cells®, the SB-1 and SB-2 are cultured in a proprietary SB cell culture media becoming SB-3 cells, which have a size between 6 to 20 µm. Once the suspended SB-3 cells attach to the bottom of the well or flask walls, they become SB-4 cells. Placed in a media for induction of differentiation, SB-4 cells have differentiated into many other kind of cells, such as neuron, muscle, and liver cells.

StemBios is a company that adheres to rigorous, creative, science acumen and a high standard of quality and service. Supported by our significant research achievements, we believe that our SB Cells® possess all the advantages of embryonic stem cells without causing immune rejection or Teratoma formation. We bring a welcomed hope towards curing neurodegenerative disease, such as Alzheimer’s and Parkinson’s, cancer, cardiovascular disease, metabolic disease, and autoimmune disease